We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0UI8 market cap is 528.94M. The company's latest EPS is USD -6.4476 and P/E is -0.03.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -26.86M | -55.77M | -65.45M | -42.6M | -52.36M |
| Net Income | -26.28M | -55.24M | -65.35M | -41.82M | -51.21M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 100.48M | 126.26M | 82.53M | 51.03M | 12.99M |
| Total Liabilities | 6.55M | 7.35M | 8.29M | 13.29M | 15.89M |
| Total Equity | 93.93M | 118.92M | 74.24M | 37.74M | -2.9M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -21.56M | -33.89M | -43.3M | -32.32M | -44.59M |
| Investing | -17.37M | 12.63M | -35.21M | 30.07M | 9.96M |
| Financing | 103.45M | 58.81M | 226k | 116k | 6.91M |
| Market Cap | 528.94M |
| Price to Earnings Ratio | -0.03 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0.15 |
| Price to Book Ratio | -0.49 |
| Dividend Yield | - |
| Shares Outstanding | 7.94M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 156 |
| 52 Week Change | 0.00% |
| 52 Week High | 66.60 |
| 52 Week Low | 66.60 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Aptose Biosciences Inc |
| Address |
5955 airport road mississauga, ontario L4V 1R9 |
| Website | https://www.aptose.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
